Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. Vertex is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad clinical pipeline in kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy type 1. Its SEC filings give investors and analysts detailed insight into financial performance, risk factors and material events affecting the business.
Recent Form 8-K filings from Vertex have reported quarterly financial results and related guidance under Item 2.02, Results of Operations and Financial Condition. These filings typically reference accompanying press releases that summarize revenue trends, research and development spending and updates across the company’s portfolio, including CFTR modulators such as ALYFTREK and TRIKAFTA, CASGEVY gene-edited cell therapy and JOURNAVX for acute pain. Other 8-K items may address changes in key executives or other corporate developments when they occur.
On Stock Titan, Vertex filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the main points of lengthy documents, so users can quickly understand how new information may relate to VRTX stock without reading every page. For example, AI summaries can highlight key themes in earnings-related 8-Ks, note significant changes in guidance or spending, and point out disclosures related to the progress of pivotal trials or regulatory submissions.
In addition to 8-Ks, users can review Vertex’s annual and quarterly reports when available, as well as any proxy materials and registration statements that may be filed. AI analysis tools on Stock Titan can surface trends across multiple filings, making it easier to track how Vertex’s financial profile and pipeline narrative evolve over time. This page is a useful starting point for anyone researching VRTX from a regulatory and disclosure perspective, complementing price charts, news and other fundamental data.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., EVP, Chief Operating Officer and Chief Financial Officer, reported two stock transactions involving the company’s common stock. He received a grant of 7,365 restricted stock units, described as an award that vests in installments beginning on February 20, 2027. This award increased his directly held shares to 51,080 immediately after the grant.
On the same date, Wagner had 2,294 shares of common stock disposed of at $483.75 per share in a transaction coded as a tax-withholding disposition to satisfy tax obligations by delivering securities. After this withholding transaction, his direct ownership stood at 48,786 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported a mix of stock transactions involving company common shares. She received a grant of 5,789 shares as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 2,294 shares were disposed of to cover tax obligations at a price of $483.75 per share. She also executed open-market sales of 609 shares at $489.46 per share and 368 shares at $473.68 per share, made under a company-approved Rule 10b5-1 trading plan entered on August 21, 2025. Following these transactions, she directly owned 48,650 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported mixed equity transactions. He received a grant of 5,789 shares of common stock as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 2,140 shares were disposed of at $483.75 per share to satisfy tax withholding obligations, leaving him with 69,042 shares held directly, plus additional common stock held indirectly through a 401(k) plan and a trust.
Vertex Pharmaceuticals executive Duncan McKechnie reported a mixed Form 4 transaction involving company stock. He acquired 4,962 shares of common stock on February 17, 2026 through a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 1,148 shares were disposed of at $483.75 per share to cover tax obligations by delivering shares, leaving him with 23,342 shares of common stock held directly.
Vertex Pharmaceuticals (common stock) reported a Form 144 notice showing proposed sales of common shares by an affiliate on various dates in 2026. The filing lists multiple lots tied to restricted stock vesting and option exercises, including 3,187; 4,318; 2,603; 23,479; and 25,026 shares on 02/10/2026, 02/13/2026, 02/17/2026, and 02/19/2026.
The notice names Fidelity Brokerage Services LLC and references NASDAQ; it reports the security type as Common and identifies several sale methods (vested restricted stock and option-related cash transactions). This is a routine affiliate sale notice under Rule 144; timing and exact sale mechanics depend on the holder's execution of the listed transactions.
Vertex Pharmaceuticals Executive Chairman Jeffrey Leiden reported a mix of equity award and tax-related share withholding. On February 17, 2026, he acquired 8,269 shares of common stock at $0.00 per share through a grant described as a restricted stock unit award that fully vested upon grant.
On February 18, 2026, 2,964 shares of common stock at $483.75 per share were disposed of in a tax-withholding disposition, a transaction type used to satisfy tax liabilities by delivering shares rather than an open-market sale. After these transactions, he directly held 38,344 shares of common stock, with an additional 440 shares held indirectly through a 401(k) account.
Vertex Pharmaceuticals CEO Reshma Kewalramani reported mixed equity transactions involving company common stock. She acquired 16,326 shares through a grant or award of restricted stock units, recorded at a price of $0.0000 per share, increasing her direct holdings at that point to 149,813 shares.
On the same date, she disposed of 6,554 shares at $483.75 per share in a tax-withholding disposition to cover exercise price or tax liabilities, leaving her with 143,259 directly held shares afterward. The footnote explains that the restricted stock unit award vests in installments beginning on February 20, 2027, meaning the granted units will become fully available over time rather than immediately.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a mix of stock sales, awards, and tax-related share dispositions. He sold 1,182 shares of common stock at $473.68 per share and 2,437 shares at $489.46 per share in open-market transactions.
He also acquired 2,584 shares through a restricted stock unit award that will vest in installments beginning on February 20, 2027, and disposed of 1,110 shares at $483.75 per share to cover tax obligations. These trades were made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025. Following the last reported transaction, he held 8,486 shares of Vertex common stock directly.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic received a grant of 5,375 shares of common stock as a restricted stock unit award that begins vesting on February 20, 2027. On the same date, 1,912 shares at $483.75 each were disposed of to cover tax withholding, leaving her with 41,516 directly owned shares.
Vertex Pharmaceuticals executive Jonathan Biller reported a mix of equity transactions in company stock. On February 17, 2026, he received a grant of 4,135 shares of common stock at $0.00 per share as a restricted stock unit award that vests in installments beginning on February 20, 2027. That same day, 1,505 shares were disposed of at $483.75 per share to cover tax obligations, and 2,476 shares were sold in open-market transactions at an average price of $489.46 per share. On February 18, 2026, he sold an additional 1,244 shares at an average price of $473.68 per share pursuant to an approved Rule 10b5-1 trading plan entered into on February 24, 2025. Following these transactions, he directly held 15,748 shares of Vertex common stock.